Xigduo XR 10/500mg Tab

Manufacturer
AstraZeneca Pharmaceuticals LP

Registraction Number
MAL16045044AZ



Content (Composition)

• Active Ingredients: Each extended-release tablet contains 10 mg dapagliflozin propanediol monohydrate (equivalent to 10 mg dapagliflozin) and 500 mg metformin hydrochloride extended-release.

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.
• Cardiovascular Risk Reduction: To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors.

• Administration: Take one tablet (10 mg/500 mg) orally once daily, preferably with the evening meal.
• Swallow Whole: Do not crush, chew, or cut the tablet.
• Renal Function Monitoring: Assess renal function prior to initiating treatment and periodically thereafter.